Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Free acid inclusion complex
What ifWhat if a cyclodextrin complex dispersed a free-acid derivative in water?
Claim language“pharmaceutically acceptable salt”
Hydroxypropylated beta-cyclodextrin associates with a hydrophobic region of the free-acid derivative through its nonpolar cavity. The hydroxyl-rich exterior contacts water, and dilution shifts the equilibrium toward release of the dissolved derivative.
1.1Nonstereogenic substituent pair
What ifWhat if two identical substituents on a side-chain carbon removed the stereocenter at that position?
Claim language“single stereoisomer”
Two methyl groups occupy the same tetrahedral carbon in the side chain. That carbon has no configurational isomers, and a different position on the side chain carries the polar group used for aqueous handling.
1.1Isolated stereoisomer for dosing
What ifWhat if one isolated stereoisomer supplied the full dose in a cell assay?
Claim language“mixture of stereoisomers”
Preparative chromatography on a chiral stationary phase separates the stereoisomers, and collection of one peak supplies the dosing material. Analytical chromatography checks stereochemical purity before the isolated fraction is diluted into the assay medium.
1.1Physical release from a polymer
What ifWhat if polymer microspheres released the active compound in its existing chemical form?
Claim language“or prodrug thereof”
Biodegradable polyester microspheres physically entrap the active compound. Water enters the particles, and drug release proceeds by diffusion through water-filled pores as hydrolysis opens the polymer matrix.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Reference samples for botanical extract analysis
A purified celastrol derivative serves as a procedural reference in a botanical extract testing laboratory. The laboratory adds the derivative to one aliquot before sample preparation and to a matched aliquot after sample preparation, then analyzes both by liquid chromatography with mass spectrometric detection. The ratio of the derivative peak areas measures its recovery during sample preparation.
Component substitution
Cyclodextrin carrier for aqueous dispersions
Hydroxypropyl beta-cyclodextrin replaces a conventional tablet filler as the excipient in a reconstitutable powder containing a celastrol derivative. The derivative is dissolved in ethanol and mixed with an aqueous cyclodextrin solution before the ethanol is removed under reduced pressure. The remaining mixture is freeze-dried, and liquid chromatography measures the dissolved derivative after the powder is reconstituted in water and filtered.
Parameter or scale variation
Microscale solubility measurements across three ph values
A 96-well filter plate holds 200 microliters of buffer per well at pH 4.0, 6.5, or 7.4. Triplicate wells at each pH receive excess solid celastrol derivative and are shaken at 25 °C for 24 hours. A 0.45-micrometer membrane retains undissolved material as the liquid passes into a collection plate, and liquid chromatography measures the derivative concentration in each filtrate.
Combination with existing systems
Inline monitoring during preparative chromatography
A preparative liquid chromatograph separates a celastrol derivative from a reaction mixture and directs its outlet through a diode-array detector to a fraction collector. An analytical injection of the purified derivative establishes a retention window and a reference absorbance spectrum for the preparative run. The collector switches to a dedicated vessel during the target peak, and mass spectrometry confirms the identity of the collected fraction.
Dialysis measurement of carrier release
A suspension containing lipid vesicles and a celastrol derivative is loaded into the donor chamber of a membrane dialysis cell. A stirred receiver chamber contains buffer, and the membrane retains the vesicles while dissolved derivative passes into the receiver. Liquid chromatography measures timed receiver samples, and a free-derivative control measures the contribution of membrane transport to the observed release profile.
Automated or data-driven variant
Automated ranking of dry storage conditions
Software assigns sealed vials containing equal masses of a celastrol derivative to controlled temperature and humidity conditions, using humidity-permeable closures for the humidity series. At each sampling time, a liquid handler reconstitutes the contents of a fresh vial in a fixed solvent volume and transfers an aliquot to a chromatography plate. The software normalizes the derivative peak area to an internal reference and ranks conditions by the fraction of the initial derivative remaining.
Specific version of a part
Sodium carboxylate salt
A derivative bearing one free carboxylic acid reacts with one molar amount of sodium hydroxide per molar amount of derivative. Freeze-drying the neutralized solution isolates the sodium carboxylate as a solid.
Defined two-epimer mixture
Two epimers with identical configurations at all other stereocenters are blended at a 1:1 molar ratio. Liquid chromatography with baseline separation and calibration for each epimer verifies the blend ratio.
Hydrolyzable ethyl ester prodrug
An ethyl ester masks the carboxylic acid of a carboxyl-bearing derivative and reduces ionization at that site. Esterase-catalyzed hydrolysis releases the free carboxylic acid and ethanol.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1A compound of structural formula (I) wherein, R1 is selected from: or a pharmaceutically acceptable salt, single stereoisomer, mixture of stereoisomers, tautomer, or prodrug thereof.
In particular, 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide intermediates are provided according to structural formula (I): including salts, hydrates, solvates and N-oxides thereof, wherein R5 is halo, fluoro, —CN, —NO2, CO2Ra or —CF3;
A · US 2005/0192301 A1 · ¶ 6
A compound of formula (I), an isomer, a solvate, or a pharmaceutically acceptable salt thereof: wherein R is independently selected from the group consisting of H, OH, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and halogen.
B · US 9,725,482 B2 · claim 1
An empty cell means only that no passage was reproduced there.
Statements in these documents
Consequently, identification of other chemotherapeutic agents, particularly active stereoisomers and/or stereoisomeric mixtures thereof is critical for establishing therapies effective for attacking the heterogeneous nature of proliferative disease and for overcoming any resistance that may develop over the course of therapy with other compounds.
A · US 2005/0192301 A1 · ¶ 5
The present invention relates to stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide intermediates that are useful for the preparation of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamides that exhibit antiproliferative activity.
A · US 2005/0192301 A1 · ¶ 2
Therefore, it is an urgent need to develop drugs with low price and good safety for treating psoriasis.
B · US 9,725,482 B2 · ¶ 4
More specifically, the present invention relates to new compounds for use in treatment of psoriasis.
B · US 9,725,482 B2 · ¶ 2
Cite aspatent.fyi, US 2026/0356879 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356879/, SHA-256 c92a2fef58a7b79d9a3f3ef6555721bb361618958af3f1b33c4ddc1872b1e4cd